In reference to $IMUN...
I'll try to respond to every comment that was made:
"I base it on looking at what they're trying to sell - a low dose version of an opioid antagonist as a treatment for AIDS. I've looked a lot of pump and dump bio but this one takes the cake for not even trying to look real. It's farcical. There's not even a plausible mechanism of action.
Hence why they're trying to get this clownshow approved in NIGERIA with non-blinded trials (zero possibility for fraud or bribery there)."
The reason why they are starting out in Africa (they hope to start selling in United States within a few years) is because they are going after their target market for AIDS, which is the African population, not the American population (read further for reason why). For other diseases, Americans will be their target market (such as Crohns, multiple sclerosis, and various cancers). Facts about LDN:
-Low-dose naltrexone (LDN) has shown promise in activating your immune system, offering impressive benefit in the treatment of cancer and autoimmune disorders
-LDN is inexpensive and is not backed by any major drug company because potential profits are minimal [exact wordage from mercola.com]. As result, it has not been widely publicized and many physicians are not familiar with it. [big pharma knows about LDN and wants it to fail because it could potentially disrupt their market - if this cheap drug is shown to work more effectively than their expensive drugs]
-LDN does not treat symptoms as most drugs do; it helps regulate bodily mechanisms that can result in a disease state
I'll restate..."potential profits are minimal". LDN will cost a patient $0.84 per day. Of this, IMUN will profit $.24 to the bottom line. This is easily enough to send the stock at least 10x from where it is, so the fact that it is cheap is not a bad things for an investor. The company will still reach profitability this year. Calculations here (I post as dwarren428 on Investors Hub, and am a moderator on that board)...
https://investorshub.advfn.com/board...e_id=131249379
So why going after Africa? Again, they are going after their target market. A pill of LDN costs $.84. Every other drug in this world that treats HIV costs $1000's per month. LDN is the only drug this cheap. Why would IMUN go into United States first? Patients in US have their insurance to pay for these expensive drugs. However, in Western Africa alone, there are 7.5 million people with HIV that are untreated because they can't afford treatment from any of these other expensive drugs. That is who IMUN is going after - an untapped market, with zero competition! I also answered this question here...
https://investorshub.advfn.com/board...e_id=130779298
And Low Dose Naltrexone has already been approved by NAFDAC (Nigerian FDA). LDN passed its final bridging trial in 2016 for HIV in Nigeria (and has also passed multiple Phase 2 studies for various diseases in the United States through its subsidiary Cytocom (in which it owns 55% of). Cytocom doesn't expect sales to begin for a few years. In reference to the bridging trial in Nigeria...
"The Control Group was treated with antiretroviral plus placebo. The primary endpoints were efficacy and safety determined by a minimum increase of 25% in the CD4 count with no adverse effects on quality of life.
The results yielded an average 44% increase in CD4 count in the Treatment Group compared with 11% increase for the Control Group and there was no adverse effect on quality of life or opportunistic infections during the trial. The Nigeria trial’s results were consistent with previous clinical trials of LDN."
This approval in Nigeria will eventually allow them to fastrack into many of the Western 15 or so African states. In my opinion, within 2 years, they'll be in most of those 15 countries. Kenya will be the 2nd most likely.
Of course, the approval of the drug itself (in 2016) was not the final step before commercialization. It has taken another year (which cost the company money of course, hence dilution) to get through all the necessary steps, and now the last step is for NAFDAC to inspect the manufacturing plant in the Dominican Republic, Acromax Dominicana. NAFDAC has already gone to inspect the plant in the D.R. IMUN is just awaiting receipt that the inspection has passed. Once this has happened, IMUN will be granted marketing approval and should begin selling right away. All deals are already in place with Fidson Healthcare in Nigeria (public company FIDSON:NL) from my understanding. Fidson will take care of marketing and we expect 150,000 patients by the 3rd month.
"Here's where you destroy your (tiny) credibility. I mean, we literally have proof of more dilution and possibly predatory lending right here in their filing from 3 days ago:"
In terms of dilution, we are at 287 million outstanding currently, and should finish right around 300 million shares. If you're really worried about that final little bit of dilution (and the market clearly has not been worried about it since 8-k came out on April 13th), then I don't know what to tell you. To each his own. Every stock gets diluted to some degree. ALL PENNY STOCKS are penny stocks for a reason. There was something wrong AT SOME POINT. IMUN is no exception. There was a lot wrong for a long time. That doesn't mean they can't turn around when dilution is over, and we are basically as close to being there as you could imagine. I definitely would not worry about trying to time it any better, because the stock is certainly looking bullish, and we are weeks or a few months from commercialization. Pretty sure the graph has already changed trajectories since April 12/13.
In terms of Ira Gaines' purchase last week...
Ira Gaines purchased 10m shares with a 6 month lockout! That $300k is probably the last cash IMUN will need in my opinion. Once they hit commercialization, all debts will be paid off within a pretty short period (only 9m debt, and should hit 4m in revenue per month by 3rd month). In addition, Ira has a warrant to purchase another 1.5m shares @.15.
This all sounds like good news to me. And it sounds like good news to the market as well (almost all buys to the ask since this 8-k was published, as opposed to sells to the bid), but of course the skeptic doesn't like it. I see that we have a investor willing to buy a huge stake (10m shares), and also agreeing to a 6 month lockout, and those 1.5 million extra shares are worthless if this stock doesn't go up to at least .15 (more than 100% increase from current price). Sounds like good news to me.
You did find things that could concern an investor about Ira Gaines. I would like you to please go into more detail about how exactly this worries you. If Ira buys 10m shares...
1) how exactly is this going to hurt the company's financial stability? It won't, it will help it.
2) how exactly will this stop NAFDAC from granting marketing approval? It won't.
3) how will it stop my shares from being worth much more in a few months when they're at 4m revenue/month? It won't.
I really don't get what you're trying to prove? Did he negotiate some wierd deal that puts him at an advantage? Well, I would say it's possible, but it still won't stop my stock from being worth way more very soon, so it is nothing to be concerned about in my opinion. If there is something I am missing, please elaborate. I would actually like to discuss this further.
"The trouble is, it's bull****. Let's take a little sanity test, shall we? This is what your website claims that a low dose of opioid antagonist can achieve:" [and the website lists 170 or so diseases]
Yes, correct. Again, it TREATS these diseases. Didn't say cure. Didn't say it works exceptionally for all of them [but I dunno, may it is exceptional for all of them]. But why so many anyway? Well they do almost all have ONE THING IN COMMON. Almost all of them are related to the immune system, so are all treated almost the same way. Not all of them are related to the immune system though.
As you said though, it is all irrelevant because LDN is already approved in Nigeria. So who cares if it treats all 170 diseases, right? At least we're good to go on the millions in Africa we'll be treating, with great potential to expand further, as IMUN does own 42 patents related to the drug. Even if it failed in everything else, the stock will still sore on HIV in Nigeria alone.
"So the very guy from your linnk says that there is no money in it (as there usually isn't in non-patentable generics). And that makes it a good thing to invest in...why?"
As I stated above, it doesn't matter. IMUN still making $.24 per pill on millions and millions of pills. They will still be on pace for $13m in annual PROFIT by 3rd month, see link...
https://investorshub.advfn.com/board...e_id=131249379
"This is what I mean about it being a low end pump and dump. It's not even clever. They've merely tagged onto a name that has some google-able details and books behind it, they hit up the forums and do things to get press releases out, and enough people think/do research as you do and swallow the BS that they keep doing secondaries and paying themselves handsome director's fees (they manage to spend $4 million/year, somehow!). It's legal theft, and it's very common; this isn't even a clever example. "
Oh yea, you sure about that? I disagree. I actually know multiple people taking LDN for various ailments, and they swear by it. But of course that means nothing to you. Here is more evidence for you though...
https://www.amazon.com/Promise-Low-D...ose+naltrexone
https://www.amazon.com/LDN-Book-Litt...RMDVB3KN4N1SRZ
https://www.youtube.com/watch?v=Kz52KK5IhOc
https://www.youtube.com/watch?v=FDCn0JWv6Io
If there was anything else that I missed or didn't respond to, it was either because I thought I already addressed it, or if I didn't, then I missed it, and then please restate so I can attempt to address / defend my argument.
Last edited by MarathonMan7; 05-11-2017 at 07:14 AM.